Onkológia S2/2023

News in the treatment of non-small cell lung cancer in the first half of 2023 in the world and new therapies in Slovakia

Lung cancer, of which the non-small cell type account for almost 85% cases, is the second most diagnosed cancer and the leading cause of cancer-related deaths worldwide. Beside this unfavourable outcome in the incidence and mortality, systemic therapy of this diagnose represents the most developing part of clinical oncology. Tyrosine-kinase inhibitors provide us various ways to treat oncogene addicted cancer, immunotherapy alone, or in combination with chemotherapy, results in significant prolongation of overall survival in precisionselected patient subgroups. In last years, combination of treatment modalities showed first promising results in treatment of localised and locally advanced NSCLC. The aim of this article is to provide the most recent updates in guidelines in 2023, review the most discussed studies presented in the first half of 2023, as well as report new recent drugs, that are available in Slovakia.

Keywords: cancer, immunotherapy, targeted therapy